-
Sotrovimab, sold
under the
brand name Xevudy, is a
human neutralizing monoclonal antibody with
activity against severe acute respiratory syndrome coronavirus...
- was
approved for
medical use in the
European Union in
November 2021.
Sotrovimab, sold
under the
brand name Xevudy, is a
human neutralizing monoclonal...
-
severe or
critical patients. It also
recommended the
monoclonal antibody Sotrovimab in
patients with non-severe disease, but only
those who are at highest...
-
neutralization tests indicate monoclonal antibody therapies (with the
exception of
sotrovimab and tixagevimab/cilgavimab) were not
likely to be
active against the Omicron...
-
Motavizumab J06BD03
Tixagevimab and
cilgavimab J06BD04
Ansuvimab J06BD05
Sotrovimab J06BD06
Regdanvimab J06BD07
Casirivimab and
imdevimab J06BD08 Nirsevimab...
- of
antigenic sites outside the RBM,
including sotrovimab (VIR-7831), S2X259 and S2H97. However,
sotrovimab was not
fully active against the BA.2 Omicron...
- 192–198. doi:10.1002/jcp.21588. PMC 2905312. PMID 18781584. "AusPAR:
Sotrovimab".
Therapeutic Goods Administration (TGA). 20
August 2021.
Archived from...
-
Odesivimab Pemivibart Rafivirumab§ Regavirumab§
Regdanvimab Sevirumab†
Sotrovimab Suptavumab Tixagevimab† (+cilgavimab)† Tuvirumab§
Chimeric Cosfroviximab...
- the
United States: bamlanivimab/etesevimab, casirivimab/imdevimab, and
sotrovimab. Bamlanivimab/etesevimab was not
recommended in the
United States due...
-
imdevimab appear to
still be effective. A
preprint study suggests that
sotrovimab may also be
effective against Delta.
Doctors in
Singapore have been using...
